Yili Zhi (宜利治)宜利治
This is a medicine registration record from NMPA data.本页为国家药监局药品注册记录。
Labeled sections from the recorded Chinese source are included below. English wording is a reference translation when one is on file, not an official English label.本记录未接入产品级适应症/安全性标注字段。
生产企业Manufacturer
- 青岛国海生物制药有限公司Chinese legal name: 青岛国海生物制药有限公司
主要成分Active Ingredients
- 甲地孕酮Jiadi Yuntong
药物知识说明
甲地孕酮是一种在国家药监局注册认定的药品。该药品含有甲地孕酮-02dc6577等成分。
该药品关联的活性成分包括：甲地孕酮Jiadi Yuntong。这些成分信息来自国家药监局数据库。
该药品标注的生产企业为：青岛国海生物制药有限公司Chinese legal name: 青岛国海生物制药有限公司。
您可以探索含有相同成分的其他药品：甲地孕酮-02dc6577成分药品。
本页面内容来自国家药监局数据库，MedicineGraph在此基础上提供关系图谱和知识导航。
Medicine Knowledge
This medicine (original name: 宜利治) is a medicine registered with the national drug regulatory authority. It contains recorded ingredients as active ingredient(s).
Active ingredients associated with this product: 甲地孕酮Jiadi Yuntong.
Manufacturers recorded for this product: 青岛国海生物制药有限公司Chinese legal name: 青岛国海生物制药有限公司.
Explore other medicines containing the same ingredient: 甲地孕酮 productsProducts containing this recorded ingredient.
Source: MedicineGraph authoritative database. Relationships derived from registered product information.
这是什么What is this
- 通用名/品名Recorded product name: 宜利治Recorded Chinese name: 宜利治
- 剂型Dosage form: 片剂Tablets
- 规格Specification: 160mg*30片160 mg × 30 tablets
本段仅展示注册/说明书已记录的身份属性，不含适应症或用法建议。Identity attributes from registration/leaflet records only; no indications or usage advice.
主要成分Ingredients
生产企业Manufacturer
- 青岛国海生物制药有限公司Chinese legal name: 青岛国海生物制药有限公司
注册信息NMPA approval number
- 批准文号NMPA approval number: 国药准字H20010074
关联实体Relationships
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据及已接入说明书字段。National Medical Products Administration (China) medicine-registration data and linked leaflet fields.
- 品名来源Name source: 10多万条药品说明书数据库 (HIGH)Package-insert database (more than 100,000 records) (HIGH)
- 生产企业来源Manufacturer source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
- 剂型来源Dosage-form source: 10多万条药品说明书数据库Package-insert database (more than 100,000 records)
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。不含适应症/安全性推断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence. No inferred indications/safety.
本段为已核准说明书原文摘录（非改写、非AI摘要），非正式英文标签，亦不构成用药建议。 Not an official English label and not medical advice. English wording, when shown, is a reference translation of the Chinese source label.
English translation for reference. Translated from the Chinese source label. Not an official English label and not medical advice.
NMPA approval number
国药准字H20010074
Manufacturer
Chinese legal name: 青岛国海生物制药有限公司 (domestically manufactured)
Indications
English translation unavailable. The original Chinese source label remains available below.
Dosage and administration
English translation unavailable. The original Chinese source label remains available below.
Adverse reactions
English translation unavailable. The original Chinese source label remains available below.
Contraindications
English translation unavailable. The original Chinese source label remains available below.
Precautions
English translation unavailable. The original Chinese source label remains available below.
Storage
Protect from light and keep tightly closed.
Specification
160 mg × 30 tablets
中文说明书原文Original Chinese source label
批准文号
国药准字H20010074
生产企业
青岛国海生物制药有限公司(国产)
适应症
本品适用于治疗晚期乳腺癌和晚期子宫内膜癌,对肾癌、前列腺癌和卵巢癌也有一定疗效。并可改善晚期肿瘤患者的食欲和恶病质。
用法用量
1.一般剂量：每次160mg，口服，每日1次。 2.高剂量：每次160mg，口服，每日2～4次。
不良反应
与其他孕酮类药物相似，但一般较轻.体重增加为本品常见不良反应，是由于体内脂肪和体细胞体积增加所致，而不一定伴有液体潴留.对于晚期癌症恶病质及体重下降患者，这种副作用常常是有益的.血栓栓塞现象罕见报道，包括血栓性静脉炎及肺动脉栓塞.其他应可引起乳房疼、溢乳、阴道流血、月经失调、脸潮红.也有肾上腺皮质醇作用，满月脸、高血压、高血糖.子宫出血发生率为1%～2%.偶见恶心及呕吐，罕见呼吸困难、心衰、皮疹等反应。
禁忌
对本品过敏者禁用。对伴有严重血栓性静脉炎、血栓栓塞性疾病、严重肝功能损害和因骨转移产生的高钙血症患者禁用。
注意事项
对接受本品治疗的患者应进行常规的密切监测,对未控制的糖尿病及高血压患者需小心使用.不主张用于乳腺癌的术后辅助治疗.禁用于妊娠诊断试验.
贮藏
遮光，密闭保存。
规格
160mg*30片
信息来源Source and scope
国家药品监督管理局（中国）药品注册数据。National Medical Products Administration (China) medicine-registration data.
范围：当前 MedicineGraph 注册记录及已记录的精确关系；非完整目录，亦不构成疗效等同主张，也不支持换用判断。Scope: current MedicineGraph registration records and exact recorded relationships; not a complete catalog and not a claim of therapeutic equivalence.